Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MindBio Therapeutics Corp C.MBIO

MindBio Therapeutics Corp. is a biotech/biopharma company. It creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. It is focused on microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. It develops a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder. The underway are two Phase 2B trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. It invests in research that forms the basis for developing novel and clinically proven treatments.


CSE:MBIO - Post by User

Post by Smokey1958on Feb 27, 2024 10:51am
95 Views
Post# 35901343

Apples to Oranges

Apples to Oranges

For whatever reason there seems to be a significantly higher number of ongoing studies with psilocybin as compared to MBio which seems almost lone wolf in trials using LSD. As is now being discussed on ceo what are the implications of this. Imho not much.

With psilocybin the focus has been on ingesting enough to create a hallucinogenic effect which requires psychiatric/psychological intervention before, during and after the treatment. Even researchers are being cautious because while potentially a very significant treatment option, it would be prohibitively expensive and time consuming at least as currently projected ....notwithstanding this is also very early stage.

Whether anything revolving around patents for MBio is possible ....it may not be necessary, as getting approval to carry out studies is still restrictive in many if not most jurisdictions ....particularly the US. It's certainly advantageous for MBio to be out of the gate early and establishing some positive results.

GLTA!!!

<< Previous
Bullboard Posts
Next >>